logo

For the Inventor, By the Inventor

Carson City, NV, United States of America

Research Development Foundation

Calculating rank
USPTO Granted Patents = 299

% Expired Patents = 33.1



Forward Citations = 2,748

Loading Chart...
Loading Chart...

291 inventors (with patents filed for the assignee):

goldMedal Michael G Rosenblum (30 out of 33 patents)

silverMedal Jere W McBride (28 out of 29 patents)

bronzeMedal David H Walker (20 out of 28 patents)

4.  Bharat B Aggarwal (19 out of 26 patents)

5.  George Georgiou (18 out of 76 patents)

6.  Wylie Walker Vale, Jr (15 out of 17 patents)

7.  Marilyn H Perrin (14 out of 25 patents)

8.  Lawrence H Cheung (13 out of 13 patents)

9.  Kathy A Lewis (13 out of 20 patents)

10.  Kimberly Kline (13 out of 13 patents)

11.  Didier Trono (12 out of 15 patents)

12.  Bob G Sanders (12 out of 12 patents)

13.  Weiping Yu (11 out of 11 patents)

14.  Wylie W Vale, Jr (11 out of 100 patents)

15.  Dennis T Brown (10 out of 11 patents)


Core Competencies:
Immunogenic Polypeptides
Engineered Antibodies
Cancer Treatment
Optical Coherence Tomography
Metabolic Diseases
Serine Protease
Probiotic Compositions
Lentiviral Vectors

299 patents:

1. 12624093 - EHRLICHIA VACCINES AND IMMUNOGENIC COMPOSITIONS (2026-05-12),
2. 12552843 - CHIMERIC IMMUNOGENIC POLYPEPTIDES (2026-02-17),
3. 12461099 - Immunoreactive polypeptides (2025-11-04),
4. 12458807 - Apparatus and methods for phase-agnostic stimuli (2025-11-04),
5. 12404332 - Methods for diagnosing and treating cancers (2025-09-02),
6. 12226468 - Immunoreactive peptides (2025-02-18),
7. 12213810 - Systems and methods for automated coronary plaque characterization and risk assessment using intravascular optical coherence tomography (2025-02-04),
8. 12171408 - Systems and methods for coronary occlusion treatment (2024-12-24),
9. 12013342 - Apparatus and methods for endometrial tissue identification (2024-06-18),
10. 11958904 - Engineered antibody Fc variants for enhanced serum half life (2024-04-16),
11. 11913043 - Cell-targeted cytotoxic constructs (2024-02-27),
12. 11883447 - Methods and probiotic compositions for the treatment of metabolic diseases and disorders (2024-01-30),
13. 11780892 - Chimeric immunogenic polypeptides (2023-10-10),
14. 11779220 - Multi-channel orthogonal convolutional neural networks (2023-10-10),
15. 11542524 - Elimination of proliferating cells from stem cell-derived grafts (2023-01-03),
Company Overview
Research Development Foundation, based in Carson City, NV, specializes in advancing immunotherapy research with a focus on innovative treatments for cancer and metabolic diseases. The organization is engaged in the development of immunogenic polypeptides and engineered antibodies, leveraging cutting-edge technologies such as optical coherence tomography and lentiviral vectors. Their work also encompasses the exploration of probiotic compositions and serine proteases, aiming to enhance therapeutic outcomes in various medical fields.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

299 Patents

#2 in Carson City, NV

#8 in Nevada

#1,466 in US

#2,994 in the World

Carson City, NV (US)
Carson City, NV, United States of America

Research Development Foundation

Forward Citations = 2,748

291 inventors:

goldMedal Michael G Rosenblum (30 out of 33 patents)

silverMedal Jere W McBride (28 out of 29 patents)

bronzeMedal David H Walker (20 out of 28 patents)

4.  Bharat B Aggarwal (19 out of 26 patents)

5.  George Georgiou (18 out of 76 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Research Development Foundation. Retrieved from https://idiyas.com/company/research-development-foundation

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…